0001209191-21-059042.txt : 20211004 0001209191-21-059042.hdr.sgml : 20211004 20211004165720 ACCESSION NUMBER: 0001209191-21-059042 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211001 FILED AS OF DATE: 20211004 DATE AS OF CHANGE: 20211004 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Crockett Thomas Andrew CENTRAL INDEX KEY: 0001690920 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36830 FILM NUMBER: 211303644 MAIL ADDRESS: STREET 1: BUILDING 227, TETRICUS SCIENCE PARK STREET 2: PORTON DOWN, SALISBURY CITY: WILTSHIRE STATE: X0 ZIP: SP4 0JQ ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001348911 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200915291 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 901E CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (857) 999-0075 MAIL ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 901E CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Therapeutics, Inc. DATE OF NAME CHANGE: 20140916 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery, Inc DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery Inc DATE OF NAME CHANGE: 20060105 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-10-01 0 0001348911 KalVista Pharmaceuticals, Inc. KALV 0001690920 Crockett Thomas Andrew C/O KALVISTA PHARMACEUTICALS, INC. 55 CAMBRIDGE PARKWAY, SUITE 901E CAMBRIDGE MA 02142 1 1 0 0 CEO Common Stock 2021-10-01 4 S 0 10000 17.1841 D 124670 D The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. /s/ Benjamin L. Palleiko, Attorney-in-Fact 2021-10-04